IRIS
GIANNINI, ALESSIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.292
EU - Europa 2.058
AS - Asia 708
SA - Sud America 153
Continente sconosciuto - Info sul continente non disponibili 99
AF - Africa 39
OC - Oceania 1
Totale 5.350
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.263
RU - Federazione Russa 455
GB - Regno Unito 453
IT - Italia 393
IE - Irlanda 239
SG - Singapore 214
CN - Cina 187
SE - Svezia 130
BR - Brasile 127
FR - Francia 100
DE - Germania 94
HK - Hong Kong 78
VN - Vietnam 75
UA - Ucraina 58
IN - India 49
FI - Finlandia 38
ES - Italia 33
ZA - Sudafrica 25
TR - Turchia 18
BD - Bangladesh 16
CA - Canada 15
BE - Belgio 13
NL - Olanda 13
PL - Polonia 10
AR - Argentina 8
IR - Iran 8
JP - Giappone 8
UZ - Uzbekistan 8
GR - Grecia 7
MX - Messico 7
SA - Arabia Saudita 7
KR - Corea 6
CZ - Repubblica Ceca 5
IQ - Iraq 5
EG - Egitto 4
NG - Nigeria 4
PY - Paraguay 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
AT - Austria 3
EC - Ecuador 3
ID - Indonesia 3
OM - Oman 3
PK - Pakistan 3
PT - Portogallo 3
BO - Bolivia 2
CO - Colombia 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
HN - Honduras 2
KG - Kirghizistan 2
LU - Lussemburgo 2
MA - Marocco 2
MY - Malesia 2
PE - Perù 2
PS - Palestinian Territory 2
AU - Australia 1
AZ - Azerbaigian 1
BH - Bahrain 1
BY - Bielorussia 1
CL - Cile 1
CY - Cipro 1
DZ - Algeria 1
EE - Estonia 1
ET - Etiopia 1
EU - Europa 1
IL - Israele 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LT - Lituania 1
LV - Lettonia 1
MN - Mongolia 1
PH - Filippine 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
TM - Turkmenistan 1
TN - Tunisia 1
Totale 5.252
Salva come PNG Salva come JPEG
Città #
Southend 398
Dallas 337
Dublin 238
Fairfield 234
Ashburn 157
Chandler 147
Moscow 135
Singapore 106
San Jose 103
Santa Clara 97
Woodbridge 91
Beijing 88
Seattle 81
Cambridge 80
Houston 80
Hong Kong 73
Siena 70
Ann Arbor 68
Milan 68
Wilmington 67
Jacksonville 52
New York 50
Princeton 39
Munich 38
Los Angeles 35
Rome 35
Council Bluffs 32
Ho Chi Minh City 27
Helsinki 25
Johannesburg 24
Lauterbourg 21
Málaga 21
Boardman 16
San Mateo 16
Atlanta 15
Dearborn 14
Hanoi 14
Brussels 13
São Paulo 13
Bengaluru 12
The Dalles 12
Izmir 11
Nanjing 11
San Diego 11
Figino 10
Fremont 10
Portsmouth 10
Buffalo 9
Manchester 9
Montreal 9
Chennai 8
London 8
Orem 8
Redwood City 8
Tashkent 8
Turin 8
Amsterdam 7
Düsseldorf 7
Frankfurt am Main 7
Mumbai 7
Redondo Beach 7
Tokyo 7
Columbus 6
Espoo 6
Indianapolis 6
Seoul 6
Warsaw 6
Belo Horizonte 5
Brasília 5
Brescia 5
Brooklyn 5
Clifton 5
Da Nang 5
Florence 5
Naples 5
North Bergen 5
Oklahoma City 5
Rio de Janeiro 5
Riyadh 5
Shanghai 5
Abuja 4
Cagliari 4
Cairo 4
Changsha 4
Chicago 4
Dhaka 4
Jinan 4
Nanchang 4
Newark 4
Phoenix 4
Roccagorga 4
Salamanca 4
San Francisco 4
Tianjin 4
Toronto 4
Turku 4
Baghdad 3
Boston 3
Brno 3
Chongqing 3
Totale 3.593
Salva come PNG Salva come JPEG
Nome #
Agreement between an in-house replication competent and a reference replication defective recombinant virus assay for measuring phenotypic resistance to HIV-1 protease, reverse transcriptase, and integrase inhibitors 335
DDX3X inhibitors, an effective way to overcome HIV-1 resistance 308
The HIV-1 reverse transcriptase E138A natural polymorphism decreases the genetic barrier to resistance to etravirine in vitro 304
(Thia)calixarenephosphonic Acids as Potent Inhibitors of the Nucleic Acid Chaperone Activity of the HIV-1 Nucleocapsid Protein with a New Binding Mode and Multitarget Antiviral Activity 303
Maraviroc as a potential HIV-1 latency-reversing agent in cell line models and ex vivo CD4 T cells 303
Structure-Based Identification of HIV-1 Nucleocapsid Protein Inhibitors Active against Wild-Type and Drug-Resistant HIV-1 Strains 301
Comparable in vitro activity of second-generation HIV-1 integrase strand transfer inhibitors (INSTIs) on HIV-1 clinical isolates with INSTI resistance mutations 299
5,6-Dihydroxypyrimidine Scaffold to Target HIV-1 Nucleocapsid Protein 263
Comparative analysis of different cell systems for Zika virus (ZIKV) propagation and evaluation of anti-ZIKV compounds in vitro 262
Development of an internally controlled quantitative PCR to measure total cell-associated HIV-1 DNA in blood 257
Performance of Geno2Pheno[coreceptor] to infer coreceptor use in human immunodeficiency virus type 1 (HIV-1) subtype A 257
Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro 254
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations 242
Synthesis and Evaluation of Bifunctional Aminothiazoles as Antiretrovirals Targeting the HIV-1 Nucleocapsid Protein 240
The HIV-1 integrase E157Q polymorphism per se does not alter susceptibility to raltegravir and dolutegravir in vitro 235
Identification of novel 2-benzoxazolinone derivatives with specific inhibitory activity against the HIV-1 nucleocapsid protein 225
HIV drug discovery and resistance testing through cell based assays 219
Development of a Cell-Based Immunodetection Assay for Simultaneous Screening of Antiviral Compounds Inhibiting Zika and Dengue Virus Replication. 211
In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients 193
External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy 165
In vitro susceptibility of HIV-1 CRF02_AG to temsavir, the active compound of the attachment inhibitor fostemsavir 142
null 32
Totale 5.350
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.077
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.077
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022456 0 59 35 51 34 28 31 28 28 42 41 79
2022/2023464 29 76 57 52 30 82 24 31 32 27 18 6
2023/2024414 14 6 35 35 4 109 139 15 1 4 5 47
2024/2025708 19 28 119 33 72 46 30 59 78 35 79 110
2025/20261.760 94 213 273 230 410 48 148 53 56 79 35 121
2026/202773 45 28 0 0 0 0 0 0 0 0 0 0
Totale 5.350